NCT06712875View on ClinicalTrials.gov

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

June 30, 2029

Conditions
Low Grade GliomaHigh Grade Glioma
Interventions
DRUG

Trametinib and Nivolumab

Trametinib combined with nivolumab (Cohort A)

DRUG

Dabrafenib, trametinib, nivolumab

Dabrafenib + trametinib combined with nivolumab (Cohort B)

Trial Locations (3)

10065

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

20010

NOT_YET_RECRUITING

Children's National Hospital, Washington D.C.

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors
lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER